Deciphera Pharmaceuticals Announces Approval of rebastinib patent in Japan

Deciphera Pharmaceuticals today announced the approval of Patent Application No. 2009-532577 by the Japanese patent office. This patent includes composition of matter protection for rebastinib and related analogs. This approval follows the previous approval and issuance of US Patent 7,790,756 in the United States and Patent No. 151529 in Singapore. These approvals represent significant milestones as Deciphera moves forward to seek patent protection for rebastinib in all major market countries. Rebastinib has completed Phase 1 safety and tolerability studies and is currently being positioned for Phase 2 evaluation in various solid tumors.